---
title: "InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AML"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304782299.md"
description: "InnoCare Pharma has dosed the first patient in a registrational Phase 3 trial in China for mesutoclax combined with azacitidine. The study compares this regimen against venetoclax plus azacitidine in elderly or unfit patients with previously untreated acute myeloid leukemia (AML). Previous results presented at ASCO 2026 indicated rapid, deep remissions with no dose-limiting toxicities. Updated findings are scheduled for presentation at the ASH Annual Meeting in December 2026."
datetime: "2026-11-09T01:33:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304782299.md)
  - [en](https://longbridge.com/en/news/304782299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304782299.md)
generator: "portal-rs"
---

# InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AML

-   InnoCare Pharma dosed the first patient in a registrational Phase 3 trial in China testing mesutoclax with azacitidine. \* The study compares the combination against venetoclax with azacitidine in elderly or unfit patients with previously untreated acute myeloid leukemia. \* Results presented at the 2026 ASCO Annual Meeting showed rapid, deep remissions with no dose-limiting toxicities. \* Updated results will be presented at the ASH Annual Meeting, scheduled for December 12-15, 2026, in New Orleans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611082033PRIMZONEFULLFEED9873002) on November 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare Pharma Reports Strong Orelabrutinib Data at ESMO](https://longbridge.com/en/news/303303500.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**